stockportfolio.pro
Stocks / ABCL vs ANAB
ABCL vs ANAB
AbCellera Biologics Inc. and AnaptysBio, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| AbCellera Biologics Inc. (ABCL) | AnaptysBio, Inc. (ANAB) | |
|---|---|---|
| Market cap | $1.6B | $1.6B |
| Revenue (latest FY) | $75.13M | $234.60M |
| Net income (latest FY) | $-146.41M | $-13.23M |
| Revenue growth (5y CAGR) | -20.3% | 25.6% |
| Net margin | -194.9% | -5.6% |
| Return on equity | -15.1% | -35.6% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 0 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ABCL — free Open ANAB — freeFrequently asked questions
Which is bigger, ABCL or ANAB?
AbCellera Biologics Inc. is larger by market capitalization — $1.6B versus $1.6B.
Which grows faster, ABCL or ANAB?
Over the last five fiscal years, AnaptysBio, Inc. grew revenue faster — 25.6%/yr versus -20.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.